LAB — STANDARD BIOTOOLS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1162194 ·
Last close
$0.54
Market Cap
$212.95M
52W High
$1.72
52W Low
$0.39
ADV30
956,869
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 19,385,000 | 10,828,000 | -8,093,000 | 13,483,000 | 635,332,000 | 267,487,000 | 79,582,000 |
| Jun 2026 | 20,104,000 | 10,535,000 | -7,829,000 | -26,758,000 | 627,218,000 | 270,026,000 | 87,247,000 |
| Mar 2026 | 21,146,000 | 11,308,000 | -9,416,000 | 127,068,000 | 639,114,000 | 265,772,000 | 77,991,000 |
| Dec 2025 | 23,795,000 | 11,382,000 | -21,924,000 | 19,283,000 | 567,754,000 | 120,863,000 | 143,463,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,259,000
Investing CF
$202,291,000
Financing CF
$-156,000
CapEx
$-2,276,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.34
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,146,754,000
Inventory
$17,617,000
Receivables
$12,982,000
ST Investments
$193,624,000
EBIT TTM
$-47,364,000
Pretax Income TTM
$-73,031,000
Interest Exp TTM
$26,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$84,430,000
EBITDA
$-38,092,000
Free Cash Flow
$166,871,248
Enterprise Value
$-183,190,272
Total Cash
$461,111,008
Total Debt
$26,834,000
Shares Out
394,790,441
Trailing EPS
$-0.09
Book Value
$1.41
ROE
-7.8%
ROA
-5.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 85,331,000 | -93,305,000 | -74,896,000 | 567,754,000 | 143,463,000 | 424,291,000 | -74,343,000 |
| Dec 2024 | 91,008,000 | -87,006,000 | -138,885,000 | 612,345,000 | 140,623,000 | 471,722,000 | -143,454,000 |
| Dec 2023 | 106,340,000 | -63,039,000 | -74,656,000 | 323,067,000 | 471,118,000 | -148,051,000 | -43,287,000 |
| Dec 2022 | 97,948,000 | -102,616,000 | -190,098,000 | 390,310,000 | 471,777,000 | -81,467,000 | -89,370,000 |
TTM Snapshot
Revenues TTM
$64,024,000
NetIncome TTM
$84,906,000
OpCashFlow TTM
—
Assets (Latest)
$627,218,000
Forward EPS
$-0.01
Max Pain — expiry 2027-02-19
max pain strike: $0.50 · spot: $0.57 · call oi: 1,316 · put oi: 12Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NGEN | NERVGEN PHARMA CORP. | $210.74M | $1.96 | — |
| PRLD | Prelude Therapeutics Inc | $216.05M | $3.32 | — |
| ACIU | AC Immune SA | $209.79M | $2.11 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $205.29M | $1.90 | — |
| KROS | Keros Therapeutics, Inc. | $221.95M | $11.31 | — |
News headlines (Yahoo Finance, 1h cache)
ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
2026-11-03 12:30 · Yahoo
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
2026-10-05 20:05 · Yahoo
Standard BioTools Provides Update on Sale of Mass Cytometry Business
2026-09-30 20:42 · Yahoo
Standard BioTools Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
2026-07-28 14:26 · Yahoo
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
2026-07-28 12:00 · Yahoo
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
2026-07-20 11:30 · Yahoo
Standard BioTools Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-06 00:30 · Yahoo
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
2026-04-21 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.